Navigation Links
The Combined Non-Small-Cell Lung Cancer Market of Argentina, Brazil and Mexico Will Grow at Six Percent Annually Through 2018
Date:12/10/2013

BURLINGTON, Mass., Dec. 10, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that, from 2013 to 2018, the non-small-cell lung cancer (NSCLC) market in Argentina, Brazil and Mexico will increase at an annual rate of six percent, reaching $495 million in 2018.

The Emerging Markets report, Non-Small-Cell Lung Cancer in Argentina, Brazil, and Mexico, also finds that changes in medical practice and reimbursement and the resulting continued uptake of targeted therapies will drive growth in this market. The market will also be sustained by a growing incident population and by the launch of 11 new branded therapies, despite limitations imposed on drug cancer coverage within the public sector.

Between 2013 and 2018, 11 novel branded NSCLC therapies will launch in Argentina, Brazil, and Mexico--Pfizer's crizotinib (which launched in Argentina and Mexico in March 2013 under brand name Xalkori), Celgene's nanoparticle paclitaxel, Boehringer Ingelheim's afatinib, Pfizer's dacomitinib, Novartis's ceritinib, Boehringer Ingelheim's nintedanib, Bristol-Myers Squibb's nivolumab, Roche's onartuzumab, Pfizer's dacomitinib, Eli Lilly's necitumumab, Eisai's eribulin and Merck & Co's MK-3475. Although the number of patients treated with these agents will be smaller compared to the world's major markets, the combined sales will comprise 16 percent of the total NSCLC market in 2018, owing to their high price.

The report, which includes primary research with Argentine, Brazilian and Mexican oncologists, also finds that the number of incident cases of NSCLC across
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Agnitio Sets Up Asia HQ in Shanghai and is the First to Bring the Combined Closed Loops of Marketing and E-Learning to the Pharmaceutical Industry
2. JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes
3. Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials to be Presented at the 2013 San Antonio Breast Cancer Conference
4. MR Solutions to Launch Two World Firsts in Pre Clinical Scanning at the World Molecular Imaging Conference in Savannah This Week - a Combined 3T, Cryogen Free MRI/PET and a 3T MRI/SPECT
5. The US Ear, Nose And Throat And Bronchoscopy Device Markets Will Reach A Combined Value Exceeding $715 Million In 2021
6. Surveyed Oncologists Indicate that the Use of Biomarker Testing is Increasing Rapidly in Non-Small-Cell Lung Cancer in China and South Korea
7. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
8. VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer
9. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
10. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
11. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... , Sep. 03, 2015 ... the addition of the "Investigation Report on China ... Oxiracetam, a derivative of pyrrolidone, was first synthesized ... whose oral preparation and injection entered the Italian market ... fast after entering China , annual ...
(Date:9/2/2015)... About Balloon Kyphoplasty VCF ... more vertebral bodies, resulting in persistent and unbearable ... is a leading cause of VCF among elderly ... tumors, and traumatic injuries also cause VCF. Individuals ... rectify the condition. Both procedures are minimally invasive ...
(Date:9/2/2015)... LONDON , Sept. 2, 2015 ... Forecasts Summary Advanced dressings have steadily ... treatment of a variety of wound indications, such ... fluid management, infection control, and physical protection become ... a greater role in standard therapy. This ...
Breaking Medicine Technology:Investigation Report on China's Oxiracetam Market, 2010-2019 2Global Balloon Kyphoplasty Market 2015-2019 2Advanced Wound Dressings - SA Analysis and Market Forecasts 2
... Confirm Robust Efficacy of CIMZIA, BOSTON, Nov. ... new,Phase III data from the RAPID 1 and ... Annual Scientific Meeting (ACR), which show,CIMZIA(R) (certolizumab pegol), ... Factor), given with methotrexate, is significantly,more effective than ...
... Fla., Nov. 7 A new analysis,presented today ... Evaluation Of Rosuvastatin) showed CRESTOR(R) (rosuvastatin calcium) 40,mg ... in four,patient populations at varying levels of risk ... subjects defined by the Framingham risk,assessment tool as ...
Cached Medicine Technology:CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 2CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 3CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 4CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 5CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 6CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 7CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 8New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 2New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 3New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 4New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 5New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 6
(Date:9/2/2015)... ... 2015 , ... Sara Bleich, Ph.D., associate professor of health ... an internationally recognized scholar on obesity prevention and control, has been selected for ... and 1996 graduate of Garrison Forest School, an all-girls’ independent school in Owings ...
(Date:9/2/2015)... ... 02, 2015 , ... The CRISPR-Cas9 system introduces double-strand DNA breaks ... nuclease with either a chimeric single guide RNA (sgRNA) or two short RNAs (a ... RNA (sgRNA or crRNA) to create a break in the target DNA that causes ...
(Date:9/2/2015)... ... September 02, 2015 , ... On ... Officers Association of America (MOAA) and Wounded Warrior Project® (WWP), will be ... Own,” expert panelists will lead interactive discussions on the responsibilities and commitments ...
(Date:9/2/2015)... ... ... According to an article published August 12 by International Business Times, a new ... with grand juries in cases meant to decide if a police officer used deadly or ... decisions in Ferguson and New York City that absolved police officers of charges in the ...
(Date:9/2/2015)... ... September 02, 2015 , ... Telehealth represents a growing trend ... to handle the telehealth services of more than 12 Blues plan clients. The ... Plans takes a look this growing trend, interviewing executives at Capital Blue Cross, whose ...
Breaking Medicine News(10 mins):Health News:Dr. Sara Bleich, Garrison Forest Graduate, Selected for 2015-16 Class of White House Fellows 2Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 2Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 3Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 4Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 2Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 3Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 2Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 3Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 2Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 3
... Today, Tuesday, January 27, 2009, 9:30 A.M.** Elected ... Community Based Health System for Embracing Courageous New Direction ... Accord Includes Free and Fair Union ... Conference to announce historic hospital accords. WHEN: Today, ...
... seize billions from state, construct prison health care centers ... lawsuit was filed this week to prevent a federal ... dollars from California,s treasury for the sole purpose of ... Safe Ventura County opposes the proposal to construct seven ...
... Fitness Industry Leader Champions Gupta,s Commitment to Enriching Quality ... 27 The American Council on Exercise (ACE), America,s ... fitness certification, education and training organizations in the world, ... Dr. Sanjay Gupta , chief medical correspondent for the ...
... (NYSE: SGP ) today reported that it ... study, a pivotal Phase III study in treatment-naive patients. ... III study in patients who failed prior treatment that ... enrolled its registration studies for boceprevir, its lead investigational ...
... (NYSE Alternext US: ILI) today announced that the Company has ... "Exchange") that outlines the Company,s strategy to regain compliance with ... Exchange to formally respond to the submitted plan within 45 ... able to continue its listing up to June 23, 2010 ...
... ANTHEM, Ariz., Jan. 27 Prime Companies, Inc. ... , The Company has begun receiving income ... , The web site is now accessible ... , , "These are major achievements and ...
Cached Medicine News:Health News:Caritas Christi, 1199SEIU, Area Trades Council to Announce Historic New Accord to Improve Health Care for Community, Patients, Health Workers 2Health News:Caritas Christi, 1199SEIU, Area Trades Council to Announce Historic New Accord to Improve Health Care for Community, Patients, Health Workers 3Health News:Caritas Christi, 1199SEIU, Area Trades Council to Announce Historic New Accord to Improve Health Care for Community, Patients, Health Workers 4Health News:Caritas Christi, 1199SEIU, Area Trades Council to Announce Historic New Accord to Improve Health Care for Community, Patients, Health Workers 5Health News:Caritas Christi, 1199SEIU, Area Trades Council to Announce Historic New Accord to Improve Health Care for Community, Patients, Health Workers 6Health News:Ventura County Taxpayers' Group Files Suit to Stop State-of-the-Art Hospitals for Incarcerated Felons 2Health News:American Council on Exercise (ACE) Endorses Appointment of Dr. Sanjay Gupta as Surgeon General of the United States 2Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 2Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 3Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 4Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 5Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 6Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 7Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 8Health News:Interleukin Genetics' Submits Plan to Regain Compliance with Continued Listing Standards 2Health News:Prime Companies Revenue Stream Begins; Dentists in Every City and Town Available on Company's New Web Site 2
... MCS + 9000 system is Haemonetics' latest ... portfolio of protocols for the collection of ... these. It also offers a range of ... of this system enables blood collection organizations ...
... The PCS2 system ... for the collection of ... allow for the collection ... platelet-poor plasma, platelet-poor plasma ...
The Plasma Extractor is used to express blood components from collection containers. The spring-loaded front panel exerts pressure on the collection container causing the fluid to transfer until cont...
... Finnpipette Stepper, a lightweight, easy-to-use ... dispensing up to 45 times ... universal Stepper handle is adapted ... cover a dispensing volume range ...
Medicine Products: